Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Corporation (BPMC) Healthcare & Pipeline Overview

Blueprint Medicines Corporation is a precision therapy company specializing in the development of targeted medicines for genomically defined cancers and blood disorders. With a focus on innovative kinase inhibitors, Blueprint Medicines aims to address unmet medical needs in oncology and hematology, competing with other biotechnology firms in a rapidly evolving market.

What Is the Investment Thesis for BPMC?

Blueprint Medicines presents a notable research candidate due to its focus on precision medicine and targeted therapies. The company's AYVAKIT and GAVRETO products have demonstrated clinical efficacy in treating specific cancers and systemic mastocytosis, driving revenue growth. With a gross margin of 96.5%, Blueprint Medicines showcases strong profitability potential. Upcoming catalysts include the continued expansion of AYVAKIT's label and the advancement of its pipeline programs, such as BLU-263 and BLU-701/BLU-945. However, the company's negative profit margin of -16.7% and competition from other biotechnology firms pose risks. The company's success hinges on its ability to successfully develop and commercialize its pipeline assets.

Based on FMP financials and quantitative analysis

BPMC Key Highlights

• Market capitalization of $8.36B reflects investor confidence in Blueprint Medicines' pipeline and commercial products.
• Gross margin of 96.5% indicates strong pricing power and efficient manufacturing processes.
• Developing AYVAKIT for systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST) addresses critical unmet medical needs.
• Collaboration agreements with Roche and Zai Lab expand the reach of Blueprint Medicines' therapies globally.
• Beta of 0.83 suggests lower volatility compared to the overall market, potentially offering stability to investors.

Who Are BPMC's Competitors?

BPMC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BPMC's Key Strengths?

• Proprietary kinase inhibitor platform
• Strong intellectual property portfolio
• Established commercial infrastructure
• Strategic collaborations with leading pharmaceutical companies

What Are BPMC's Weaknesses?

• Negative profit margin
• Reliance on key products
• Competition from other biotechnology firms
• Regulatory and pricing pressures

What Could Drive BPMC Stock Higher?

• Potential FDA approval for expanded use of AYVAKIT in additional indications for systemic mastocytosis.
• Clinical trial results for BLU-263 in non-advanced systemic mastocytosis expected in late 2026.
• Progress in the development of BLU-701 and BLU-945 for EGFR-driven non-small cell lung carcinoma.
• Continued revenue growth from GAVRETO through the collaboration with Roche.

What Are the Key Risks for BPMC?

• Negative return on equity (-15.4%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $15.0M recently.
• Clinical trial failures for pipeline programs could negatively impact investor sentiment.
• Regulatory setbacks or delays in drug approvals could delay commercialization efforts.
• Competition from other biotechnology firms could erode market share.
• Pricing pressures and reimbursement challenges could impact profitability.
• Dependence on key products like AYVAKIT and GAVRETO creates vulnerability to competition and patent expirations.

What Are the Growth Opportunities for BPMC?

• Expansion of AYVAKIT Label: Blueprint Medicines has the opportunity to expand the label for AYVAKIT to include additional indications within systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). This expansion could significantly increase the addressable patient population and drive revenue growth. The market for SM therapies is estimated to reach $1 billion by 2030, providing a substantial opportunity for Blueprint Medicines. This expansion is expected within the next 2-3 years.
• Advancement of BLU-263 for Non-Advanced SM: BLU-263, an orally available KIT inhibitor, represents a significant growth opportunity for Blueprint Medicines in the treatment of non-advanced SM and other mast cell disorders. The market for non-advanced SM therapies is underserved, and BLU-263 has the potential to become a best-in-class treatment option. Clinical trials are ongoing, with potential for regulatory submission within the next 3-4 years.
• Development of BLU-701 and BLU-945 for EGFR-Driven NSCLC: Blueprint Medicines is developing BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung carcinoma (NSCLC). The market for EGFR-targeted therapies is substantial, with sales exceeding $10 billion annually. These therapies could address resistance mechanisms and improve outcomes for patients with EGFR-mutated NSCLC. Clinical trials are underway, with potential for market entry within the next 4-5 years.
• Collaboration with Roche for GAVRETO: Blueprint Medicines' collaboration with Roche for GAVRETO provides a significant growth opportunity through expanded global reach and commercialization efforts. Roche's expertise and resources can accelerate the adoption of GAVRETO in RET fusion-positive NSCLC and other solid tumors. This collaboration is expected to drive revenue growth and market penetration over the next several years.
• Pipeline Expansion into New Therapeutic Areas: Blueprint Medicines is actively expanding its pipeline into new therapeutic areas, including fibrodysplasia ossificans progressive (FOP) and cyclin E aberrant cancers. These programs represent long-term growth opportunities and diversify the company's portfolio beyond its core focus on kinase inhibitors. Clinical development is in early stages, with potential for future market entry in the next 5-7 years.

What Opportunities Does BPMC Have?

• Expansion of AYVAKIT label
• Advancement of BLU-263 for non-advanced SM
• Development of BLU-701 and BLU-945 for EGFR-driven NSCLC
• Pipeline expansion into new therapeutic areas

What Threats Does BPMC Face?

• Clinical trial failures
• Regulatory setbacks
• Patent expirations
• Competition from biosimilars

What Are BPMC's Competitive Advantages?

• Proprietary Kinase Inhibitor Platform: Blueprint Medicines has a proprietary platform for developing highly selective kinase inhibitors, providing a competitive advantage in targeting specific disease-driving mutations.
• Strong Intellectual Property Portfolio: The company has a strong intellectual property portfolio protecting its products and technologies, creating barriers to entry for competitors.
• Established Commercial Infrastructure: Blueprint Medicines has an established commercial infrastructure for marketing and selling its products, enabling it to effectively reach patients and healthcare providers.
• Strategic Collaborations: The company has strategic collaborations with leading pharmaceutical companies, providing access to resources and expertise that enhance its drug development and commercialization efforts.

What Does BPMC Do?

Blueprint Medicines Corporation, founded in 2008 and headquartered in Cambridge, Massachusetts, is a global precision therapy company dedicated to improving the lives of patients with genomically defined diseases. Originally named Hoyle Pharmaceuticals, Inc., the company rebranded in 2011 to reflect its focus on developing targeted therapies. Blueprint Medicines develops innovative kinase inhibitors designed to selectively target and inhibit specific disease-driving mutations. Their portfolio includes AYVAKIT (avapritinib) for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST), and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid carcinoma, and other solid tumors. The company is also advancing a pipeline of preclinical and clinical programs targeting various cancers and blood disorders, including BLU-263 for non-advanced SM, Fisogatinib for hepatocellular carcinoma, and BLU-701/BLU-945 for EGFR-driven NSCLC. Blueprint Medicines collaborates with several pharmaceutical companies, including F. Hoffmann-La Roche Ltd and Zai Lab, to expand the reach of its therapies and accelerate drug development. With a team of 682 employees, Blueprint Medicines is committed to delivering transformative medicines to patients with significant unmet needs.

What Products and Services Does BPMC Offer?

• Develop precision medicines for genomically defined cancers and blood disorders.
• Create kinase inhibitors to target specific disease-driving mutations.
• Offer AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST).
• Provide GAVRETO for RET fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors.
• Advance a pipeline of preclinical and clinical programs targeting various cancers and blood disorders.
• Collaborate with pharmaceutical companies to expand the reach of its therapies.
• Focus on improving the lives of patients with significant unmet medical needs.

How Does BPMC Make Money?

• Develop and commercialize targeted therapies for genomically defined diseases.
• Generate revenue through sales of AYVAKIT and GAVRETO.
• Establish collaboration agreements with pharmaceutical companies for drug development and commercialization.
• Out-license certain rights to its products in specific geographic regions.
• Invest in research and development to expand its pipeline of innovative therapies.

What Industry Does BPMC Operate In?

Blueprint Medicines operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for targeted cancer therapies is growing, driven by advances in genomics and personalized medicine. Blueprint Medicines competes with companies like ROIV: Roivant Sciences Ltd., KRTX: Karuna Therapeutics, IMGN: ImmunoGen, and ISEE: IVERIC bio, Inc., all vying for market share in oncology and hematology. The industry is also subject to regulatory scrutiny and pricing pressures, which can impact profitability. The company's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs.

Who Are BPMC's Key Customers?

• Patients with genomically defined cancers and blood disorders.
• Oncologists and hematologists who prescribe Blueprint Medicines' therapies.
• Hospitals and clinics that administer Blueprint Medicines' products.
• Pharmaceutical companies that collaborate with Blueprint Medicines on drug development and commercialization.

Company Profile

Blueprint Medicines Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Kathryn Haviland. BPMC has traded publicly since 2015.

ROE -15%Key Financial Metrics

Return on equity for Blueprint Medicines Corporation stands at -15.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.6%, the inverse of the P/E and a quick read on earnings relative to price.

BPMC Valuation & Market Position

With a $8.36B market cap, Blueprint Medicines Corporation sits in the mid-cap segment of the market. Relative to its peer group, BPMC's quantitative score of 46/100 is roughly in line with the peer average of 51/100.

Quarterly Financial Performance: Blueprint Medicines Corporation

Revenue for Blueprint Medicines Corporation came in at $149.4M during Q1 2025, a 2.1% improvement versus the preceding quarter. The company recorded net income of $496K, with diluted EPS of $0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, BPMC averaged $-0.62 in diluted EPS.

F-Score 4/9Financial Health

Blueprint Medicines Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.68 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Blueprint Medicines Corporation revenue of about $953.9M for fiscal 2026, with EPS near $0.92. The estimate reflects 10 contributing analysts.

Net sellingInsider Activity

The most recent 12 insider filings for Blueprint Medicines Corporation break down as 11 sales and 1 purchases. On net that is roughly 277K shares disposed (about $15.0M), a signal worth weighing alongside the fundamentals.

BPMC Financials

BPMC Latest News

No recent news available for BPMC.

BPMC Analyst Consensus

BPMC MoonshotScore

BPMC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources